Literature DB >> 6257444

Regulation of norepinephrine release by peripheral alpha 2-receptor stimulation.

G A FitzGerald, J Watkins, C T Dollery.   

Abstract

Although extensive evidence obtained in animals and in vitro supports the existence of an alpha-receptor-mediated inhibitory regulation of norepinephrine release, the importance of such a system in man is not established. Norepinephrine release was physiologically stimulated by change of posture and dynamic exercise in subjects while they were infused with phenylephrine, a predominant alpha 1-receptor agonist, alpha-methylnorepinephrine, a predominant alpha 2-agonist, and saline. Agonist infusions were administered both at rates that induced a slight elevation in supine systolic pressure and at nonpressor rates. Agonist concentrations that induced much the same pressor responses (alpha 1) were assumed on the basis of in vitro experiments to differ substantially in their affinity for alpha 2-receptors. The hemodynamic response and the increase of plasma norepinephrine induced by changes in posture and exercise were of the same order during infusions of alpha-methylnorepinephrine, phenylephrine, and saline. Similar results from the "nonpressor" as from "pressor" agonist infusions suggested that baroreflex-induced reduction in sympathetic neuronal activity had not confounded the results. Correction of plasma concentrations for individual values of norepinephrine clearance provided an index of norepinephrine release into the circulation that was not changed by phenylephrine or alpha-methylnorepinephrine. These results raise the question of the importance of peripheral alpha 2-receptors in the regulation of norepinephrine release in man.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6257444     DOI: 10.1038/clpt.1981.26

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin.

Authors:  M G Scott; A H Deering; M T McMahon; D W Harron; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Cardiovascular effects of indoramin in man--a dose ranging study.

Authors:  D P Nicholls; D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

3.  The physiological and pharmacological role of presynaptic alpha- and beta-adrenoceptors in man.

Authors:  M J Brown; A D Struthers; J M Burrin; L Di Silvio; D C Brown
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

4.  Differential blockade of alpha-adrenoceptors by indoramin.

Authors:  D P Nicholls; P C O'Connor; D W Harron; W J Leahey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

5.  A hypothesis to explain the presynaptic effects of adrenoceptor antagonists.

Authors:  S Kalsner; M Quillan
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

6.  Evidence for a physiological role of presynaptic alpha-adrenoceptors: modulation of noradrenaline release in the pithed rabbit.

Authors:  H Majewski; L Hedler; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-12       Impact factor: 3.000

7.  The effects of yohimbine on presynaptic and postsynaptic events during sympathetic nerve activation in cattle iris: a critique of presynaptic receptor theory.

Authors:  S Kalsner
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

8.  Baroreceptor function in man following peripheral alpha 1- and alpha 2-adrenoceptor stimulation.

Authors:  A H Deering; J G Riddell; R G Shanks; D W Harron
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.